ociperlimab
Showing 1 - 9 of 9
Triple Negative Breast Cancer Trial (Ociperlimab, Tislelizumab, Paclitaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Ociperlimab
- +7 more
- (no location specified)
Mar 30, 2023
NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Ociperlimab
- +8 more
- (no location specified)
Mar 17, 2023
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (Ociperlimab, Tislelizumab,
Recruiting
- Relapsed Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma
- Ociperlimab
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
May 4, 2022
Non Small Cell Lung Cancer Trial (Tislelizumab, Ociperlimab, LBL-007)
Not yet recruiting
- Non Small Cell Lung Cancer
- Tislelizumab
- +2 more
- (no location specified)
Jan 30, 2023
Advanced Hepatocellular Carcinoma Trial in China, Taiwan (Ociperlimab, Tislelizumab, BAT1706)
Recruiting
- Advanced Hepatocellular Carcinoma
- Ociperlimab
- +2 more
-
Beijing, Beijing, China
- +24 more
Nov 19, 2021
Esophageal Squamous Cell Carcinoma Trial in Worldwide (Tislelizumab, Ociperlimab, Placebo)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Tislelizumab
- +2 more
-
Hefei, Anhui, China
- +85 more
Aug 19, 2022
Locally Advanced and Metastatic Solid Tumors Trial in Worldwide (Ociperlimab, Tislelizumab, Pemetrexed)
Recruiting
- Locally Advanced and Metastatic Solid Tumors
- Ociperlimab
- +10 more
-
Phoenix, Arizona
- +66 more
May 16, 2022
NSCLC, NSCLC Trial in Worldwide (Tislelizumab, Ociperlimab, Pembrolizumab)
Recruiting
- Non-small Cell Lung Cancer
- NSCLC
- Tislelizumab
- +3 more
-
Birmingham, Alabama
- +223 more
May 24, 2022